PDF(Pubmed)
Abstract：
UNASSIGNED: COVID-19 has caused severe morbidity and mortality worldwide. After the end of the dynamic zero-COVID policy in China in December, 2022, concerns regarding reinfection were raised while little was known due to the lack of surveillance data in this country.
UNASSIGNED: This study reviews the probability, risk factors, and severity of severe acute respiratory syndrome coronavirus 2 Omicron variant reinfection, as well as the interval between infections, risk of onward transmission by reinfected cases, and the role of booster vaccination against reinfection.
UNASSIGNED: References for this review were identified through searches of PubMed and Web of Science up to September 24, 2023.
UNASSIGNED: The rate of reinfection ranges from 3.1% to 13.0%. Factors associated with a higher risk of reinfection include being female, having comorbidities, and being unvaccinated. Reinfection with the BA.4 or BA.5 variant occurs approximately 180 days after the initial infection. Reinfections are less clinically severe than primary infections, and there is evidence of lower transmissibility. The debate surrounding the effectiveness and feasibility of booster vaccinations in preventing reinfection continues.
UNASSIGNED: The reinfection rate during the Omicron epidemic is significantly higher than in previous epidemic periods. However, the symptoms and infectivity of reinfection were weaker than those of the prior infection. Medical staff and individuals at high risk of reinfection should be vigilant. The efficacy of booster vaccinations in reducing reinfection is currently under debate.
UNASSIGNED: This study reviews the probability, risk factors, and severity of severe acute respiratory syndrome coronavirus 2 Omicron variant reinfection, as well as the interval between infections, risk of onward transmission by reinfected cases, and the role of booster vaccination against reinfection.
UNASSIGNED: References for this review were identified through searches of PubMed and Web of Science up to September 24, 2023.
UNASSIGNED: The rate of reinfection ranges from 3.1% to 13.0%. Factors associated with a higher risk of reinfection include being female, having comorbidities, and being unvaccinated. Reinfection with the BA.4 or BA.5 variant occurs approximately 180 days after the initial infection. Reinfections are less clinically severe than primary infections, and there is evidence of lower transmissibility. The debate surrounding the effectiveness and feasibility of booster vaccinations in preventing reinfection continues.
UNASSIGNED: The reinfection rate during the Omicron epidemic is significantly higher than in previous epidemic periods. However, the symptoms and infectivity of reinfection were weaker than those of the prior infection. Medical staff and individuals at high risk of reinfection should be vigilant. The efficacy of booster vaccinations in reducing reinfection is currently under debate.
摘要：
■COVID-19在全球范围内造成了严重的发病率和死亡率。在中国12月结束动态零COVID政策之后，2022年，人们提出了对再感染的担忧，而由于该国缺乏监测数据，人们对此知之甚少。
■本研究回顾了概率，危险因素，严重急性呼吸综合征冠状病毒2Omicron变异型再感染的严重程度，以及感染之间的间隔，再感染病例继续传播的风险，以及加强疫苗接种预防再感染的作用。
■本评论的参考文献是通过截至2023年9月24日的PubMed和WebofScience搜索确定的。
■再感染率为3.1％至13.0％。与更高的再感染风险相关的因素包括女性，有合并症，没有接种疫苗。在初次感染后约180天发生BA.4或BA.5变体的再感染。再感染在临床上不如原发感染严重，有证据表明传播性较低。围绕加强疫苗预防再感染的有效性和可行性的争论仍在继续。
■Omicron流行期间的再感染率明显高于以前的流行期。然而,再感染的症状和传染性比以前的感染要弱。医务人员和高危再感染的个人应保持警惕。加强疫苗接种在减少再感染方面的功效目前正在辩论中。
■本研究回顾了概率，危险因素，严重急性呼吸综合征冠状病毒2Omicron变异型再感染的严重程度，以及感染之间的间隔，再感染病例继续传播的风险，以及加强疫苗接种预防再感染的作用。
■本评论的参考文献是通过截至2023年9月24日的PubMed和WebofScience搜索确定的。
■再感染率为3.1％至13.0％。与更高的再感染风险相关的因素包括女性，有合并症，没有接种疫苗。在初次感染后约180天发生BA.4或BA.5变体的再感染。再感染在临床上不如原发感染严重，有证据表明传播性较低。围绕加强疫苗预防再感染的有效性和可行性的争论仍在继续。
■Omicron流行期间的再感染率明显高于以前的流行期。然而,再感染的症状和传染性比以前的感染要弱。医务人员和高危再感染的个人应保持警惕。加强疫苗接种在减少再感染方面的功效目前正在辩论中。
